GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
|Year of publication||2022|
|Type||Article in Periodical|
|Magazine / Source||TRENDS IN ENDOCRINOLOGY AND METABOLISM|
|MU Faculty or unit|
|Keywords||antipsychotic; metabolic adverse effects; GLP-1 receptor agonist; pro-cognitive; schizophrenia|
|Description||Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impair-ment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.|